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Methods: A prospective studywas conducted to characterize
the pharmacokinetics (PK) of ﬂudarabine plasma (f-ara-A)
and intracellular triphosphate (f-ara-ATP) in children
undergoing alloHCT and receiving ﬂudarabine with their
conditioning regimen. Plasma and peripheral blood mono-
nuclear cells (PBMCs) were collected over the 3-5 days of
ﬂudarabine treatment for quantitation of f-ara-A and f-ara-
ATP, respectively, using a validated liquid chromatography/
tandem mass spectrometry assay. Nonlinear mixed effects
modeling was used to develop the population PK model,
including identiﬁcation of covariates that inﬂuenced drug
disposition.
Results: Fifty-four children (median age 2 years, range 0.25-
17) undergoing alloHCT for a variety of malignant and
nonmalignant disorders underwent PK assessments. A 2-
compartment model with linear elimination best described
the PK of f-ara-A while a third compartment representing
PBMCs linked f-ara-A to f-ara-ATP. Final parameter estimates
and relative standard errors for f-ara-A are as follows:
clearance, 5.8 L/h (5.4%), volume of central compartment,
16.6 L (9.0%), volume of peripheral compartment, 16.6 L
(5.8%), and intercompartmental clearance, 3.0 L/h (14.1%).
Covariates signiﬁcantly impacting f-ara-A clearance included
body weight, age, and creatinine clearance (CrCL). Dose-
normalized PK exposure was highest among very small,
young children or subjects with renal dysfunction. Predicted
f-ara-A clearancewas reduced 40% in subjects with CrCL 50
mL/min compared to those with normal renal function (120
mL/min). Additionally, the rate of f-ara-A into PBMCs and/or
transformation to f-ara-ATP (modeled with a ﬁrst order rate
constant) decreased over the course of therapy, resulting in
42% lower intracellular f-ara-ATP exposure following the
third versus ﬁrst dose.
Impact: These results will help inform better dosing strate-
gies for ﬂudarabine, particularly in young infants with small
body size or in children with pre-existing renal dysfunction.
Re-evaluation of the optimal dosing regimen for ﬂudarabine
is warranted given the decrease in intracellular exposure to f-
ara-ATP with time.12
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AlloPBHCT compared to bone marrow transplants have a
decreased time to engraftment due to higher levels of CD34+
cells in the graft. However, the correlation of CD34+, CD3+,
CD4+, CD8+ and total nucleated cell (TNC) dose with out-
comes after alloPBHCT have been inconsistent. We retro-
spectively analyzed graft cell composition, focusing on
conditioning regimen intensity +/- total body irradiation
(TBI), in 254 consecutive ﬁrst alloPBHCT patients from 1/
2001 to 9/2012. Patient characteristics are: 58% male, 76%
40 years, 56% related/44% unrelated donor, 44% AML, 18%
MDS/MPD, 13% ALL, 13% NHL, 12% other diseases, 49% in CR
pre-PBHCT. 94 patients hadmyeloablative (MA) conditioning
with (n¼53) or without (n¼41) TBI. 160 patients had reduced
